The SIILTIBCY test is now available worldwide through the STOP TB GDF for $1.50 per dose. This novel testing option provides an alternative to PPD testing and is the first MTB antigen based skin test to be approved and recommended by the Global Fund’s Expert Review Panel. This new test has been shown to provide greater specificity in detecting TB in patients who received the BCG vaccine. Read more here.
top of page
Recent Posts
See AllA new study revealed that resistance is developing to the 6-month BPaLM regimen recommended by the WHO. The study investigated around...
Preliminary findings from the phase 1B PanACEA trial shows promising results for a new antibiotic, BTZ-043. The aim is to create an...
A new initiative in Nigeria aims to provide state health insurance to any patient with drug resistant TB in the country. Implementation...
bottom of page
Comments